Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Mucus may block inhaled antibodies in lung disease

NCT ID NCT06670937

Knowledge-focused Sponsor: University Hospital, Tours Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how mucus from the airways of people with bronchiectasis affects a new inhaled antibody treatment. Researchers will collect sputum samples from 30 adults with stable bronchiectasis and test how well the antibodies can reach and bind to bacteria in the lab. The goal is to understand barriers to this therapy and help design better inhaled treatments for chronic lung infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Dec 2024

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Clinical diagnosis of NCFB * Computed tomography (CT) evidence of bilateral bronchiectasis * Consent for research use of data and material * Ability to provide an induced sputum sample * Stable clinical status over the last 4 weeks Exclusion Criteria: * Pulmonary disease other than NCFB (except asthma) * Diagnosis of cystic fibrosis * Diagnosis of primary ciliary dyskinesia * Requirement for oxygen therapy at rest * Diagnosis of IgG deficiency (total serum IgG \< 5.4 g/l) * Treatment with a CFTR modulator drug in the last 6 months * Unilateral bronchectasis * CT evidence of interstitial lung disease with traction bronchectasis * Refusal of the patient * Acute exacerbation of NFCB in the last 4 weeks * No sputum production * Current treatment with systemic antibiotics (other than low dose azithromycin) * Pregnancy or breastfeeding * Subject under legal protection (e.g., guardianship, tutorship). * Inability to produce a sputum sample

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bronchiectasis adult are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bronchiectasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bronchiectasis adult

Contacts and locations

Locations

  • CHRU de Tours

    Tours, France, 37044, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.